Effects of empagliflozin on cardiovascular and renal outcomes in heart failure with reduced ejection fraction according to age: a secondary analysis of EMPEROR‐Reduced
Why the study?
Empagliflozin improves cardiovascular and renal outcomes in HFrEF, but its efficacy and safety across age groups was not well established.
Does empagliflozin improve cardiovascular and renal outcomes consistently across age groups in patients with symptomatic HFrEF?
Population
3730 symptomatic HFrEF patients with LVEF ≤40% and elevated natriuretic peptides, stratified by age
Comparison
Empagliflozin 10 mg daily vs placebo added to standard HF therapy
Design
Secondary analysis of a randomized controlled trial
Authors
Discussion
Loading...
Member takes
Implication
Supports empagliflozin in HFrEF across all ages including ≥75 years; confirms consistent benefit without age interaction.
Structured PICO
Does empagliflozin improve cardiovascular and renal outcomes consistently across age groups in patients with symptomatic HFrEF?
P
Population
3,730 symptomatic HFrEF patients with a left ventricular ejection fraction ≤40% and increased natriuretic peptides, stratified by age (<65, 65–74, ≥75 years)
I
Intervention
Empagliflozin 10 mg daily added to standard HF therapy
C
Comparator
Placebo added to standard HF therapy
O
Outcome
Composite of cardiovascular death or HF hospitalizationcomposite
Empagliflozin safely and effectively improves cardiovascular and renal outcomes in patients with HFrEF across all age groups, including older adults aged ≥75 years.
Cite This Study
Filippatos et al. (2022) studied this question.